Mydecine Innovations Group recently signed a five-year agreement with Johns Hopkins University School of Medicine that will advance research on novel psychedelic therapy.
Co-founder and CEO Anthony Tennyson spoke to Psychedelic Health about Awakn’s mission to transform mental health and addiction care through psychedelics.
Ketamine One Capital and Cognetivity Neurosciences have entered into a partnership to study and develop assessments for depression and post-traumatic stress disorder (PTSD).
The US Food and Drug Administration (FDA) has given authorisation for a Phase II clinical trial to evaluate psychedelic-assisted psychotherapy for frontline clinicians who are experiencing...
The non-profit Mind Medicine Australia will be hosting the summit that will bring together leaders in the field of psychedelics to discuss the benefits of the...
A small study has reported that two doses of psilocybin received with supportive psychotherapy relieves depression.
Braxia Scientific Corp.
A first-of-its-kind study will investigate the use of MDMA-assisted psychotherapy for the treatment of female Hypoactive Sexual Desire Disorder (HSDD).
Tryp Therapeutics has completed psychotherapy training for its upcoming Phase 2a psilocybin clinical trial.
People will now be able to participate in psychedelic-assisted therapy in a group setting as the Institute for Integrative Therapies expands its services to support the...
